Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) is a public company focused on developing and commercializing health innovation platforms. Ignite Proteomics is currently a 100%-owned subsidiary of Aditxt. Through the proposed business combination, Aditxt expects to unlock value in Ignite at an implied equity value of approximately $150 million, while Ignite is expected to become an independent publicly traded company. Aditxt is expected to continue as a separate Nasdaq-listed public company, subject to continued compliance with Nasdaq listing requirements.

Current securities

1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 23, 2026
2. Other EventsAug 19, 2026
3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 17, 2026
4. SCHEDULE 13G - filed by Castillo Christopher regarding Aditxt, Inc.Jul 2, 2026
5. SCHEDULE 13G - filed by WOJCIK JERZY STANISLAW regarding Aditxt, Inc.Jun 26, 2026